156 related articles for article (PubMed ID: 24939622)
61. Histone deacetylase inhibitor valproic acid inhibits proliferation and induces apoptosis in KM3 cells via downregulating VEGF receptor.
Dong XF; Song Q; Li LZ; Zhao CL; Wang LQ
Neuro Endocrinol Lett; 2007 Dec; 28(6):775-80. PubMed ID: 18063935
[TBL] [Abstract][Full Text] [Related]
62. Valproic acid attenuates acute lung injury induced by ischemia-reperfusion in rats.
Wu SY; Tang SE; Ko FC; Wu GC; Huang KL; Chu SJ
Anesthesiology; 2015 Jun; 122(6):1327-37. PubMed ID: 25749053
[TBL] [Abstract][Full Text] [Related]
63. Design of composite inhibitors targeting glutamate carboxypeptidase II: the importance of effector functionalities.
Novakova Z; Cerny J; Choy CJ; Nedrow JR; Choi JK; Lubkowski J; Berkman CE; Barinka C
FEBS J; 2016 Jan; 283(1):130-43. PubMed ID: 26460595
[TBL] [Abstract][Full Text] [Related]
64. Induction of neurotrophic and differentiation factors in neural stem cells by valproic acid.
Almutawaa W; Kang NH; Pan Y; Niles LP
Basic Clin Pharmacol Toxicol; 2014 Aug; 115(2):216-21. PubMed ID: 24460582
[TBL] [Abstract][Full Text] [Related]
65. A high-resolution structure of ligand-free human glutamate carboxypeptidase II.
Barinka C; Starkova J; Konvalinka J; Lubkowski J
Acta Crystallogr Sect F Struct Biol Cryst Commun; 2007 Mar; 63(Pt 3):150-3. PubMed ID: 17329803
[TBL] [Abstract][Full Text] [Related]
66. The synergistic effects of DNA-damaging drugs cisplatin and etoposide with a histone deacetylase inhibitor valproate in high-risk neuroblastoma cells.
Groh T; Hrabeta J; Khalil MA; Doktorova H; Eckschlager T; Stiborova M
Int J Oncol; 2015 Jul; 47(1):343-52. PubMed ID: 25963435
[TBL] [Abstract][Full Text] [Related]
67. Low dosed interferon alpha augments the anti-tumor potential of histone deacetylase inhibition on prostate cancer cell growth and invasion.
Hudak L; Tezeeh P; Wedel S; Makarević J; Juengel E; Tsaur I; Bartsch G; Wiesner C; Haferkamp A; Blaheta RA
Prostate; 2012 Dec; 72(16):1719-35. PubMed ID: 22473339
[TBL] [Abstract][Full Text] [Related]
68. Rational design of urea-based glutamate carboxypeptidase II (GCPII) inhibitors as versatile tools for specific drug targeting and delivery.
Tykvart J; Schimer J; Bařinková J; Pachl P; Poštová-Slavětínská L; Majer P; Konvalinka J; Šácha P
Bioorg Med Chem; 2014 Aug; 22(15):4099-108. PubMed ID: 24954515
[TBL] [Abstract][Full Text] [Related]
69. Neuroprotective effects of valproic acid following transient global ischemia in rats.
Xuan A; Long D; Li J; Ji W; Hong L; Zhang M; Zhang W
Life Sci; 2012 Mar; 90(11-12):463-8. PubMed ID: 22285595
[TBL] [Abstract][Full Text] [Related]
70. Impact of histone deacetylase inhibitor valproic acid on the anticancer effect of etoposide on neuroblastoma cells.
Groh T; Hrabeta J; Poljakova J; Eckschlager T; Stiborova M
Neuro Endocrinol Lett; 2012; 33 Suppl 3():16-24. PubMed ID: 23353839
[TBL] [Abstract][Full Text] [Related]
71. [Inhibitory effect of valproic acid on xenografted Kasumi-1 tumor growth in nude mouse and its mechanism].
Liu P; Tian X; Shi GR; Jiang FY; Liu BQ; Zhang ZH; Zhao L; Yan LN; Liang ZQ; Hao CL
Zhonghua Xue Ye Xue Za Zhi; 2011 Jul; 32(7):458-62. PubMed ID: 22213865
[TBL] [Abstract][Full Text] [Related]
72. Paradoxical role of C1561T glutamate carboxypeptidase II (GCPII) genetic polymorphism in altering disease susceptibility.
Divyya S; Naushad SM; Addlagatta A; Murthy PV; Reddy ChR; Digumarti RR; Gottumukkala SR; Kumar A; Rammurti S; Kutala VK
Gene; 2012 Apr; 497(2):273-9. PubMed ID: 22310383
[TBL] [Abstract][Full Text] [Related]
73. Clinical utility of genetic variants of glutamate carboxypeptidase II in predicting breast cancer and prostate cancer risk.
Naushad SM; Shree Divyya P; Janaki Ramaiah M; Alex Stanley B; Prasanna Lakshmi S; Vishnupriya J; Kutala VK
Cancer Genet; 2015 Nov; 208(11):552-8. PubMed ID: 26471812
[TBL] [Abstract][Full Text] [Related]
74. Reaction mechanism of glutamate carboxypeptidase II revealed by mutagenesis, X-ray crystallography, and computational methods.
Klusák V; Barinka C; Plechanovová A; Mlcochová P; Konvalinka J; Rulísek L; Lubkowski J
Biochemistry; 2009 May; 48(19):4126-38. PubMed ID: 19301871
[TBL] [Abstract][Full Text] [Related]
75. Glutamate carboxypeptidase II in diagnosis and treatment of neurologic disorders and prostate cancer.
Bařinka C; Rojas C; Slusher B; Pomper M
Curr Med Chem; 2012; 19(6):856-70. PubMed ID: 22214450
[TBL] [Abstract][Full Text] [Related]
76. Structure-activity relationships of glutamate carboxypeptidase II (GCPII) inhibitors.
Ferraris DV; Shukla K; Tsukamoto T
Curr Med Chem; 2012; 19(9):1282-94. PubMed ID: 22304717
[TBL] [Abstract][Full Text] [Related]
77. Valproic Acid Induces Autism-Like Synaptic and Behavioral Deficits by Disrupting Histone Acetylation of Prefrontal Cortex ALDH1A1 in Rats.
Liu H; Tan M; Cheng B; Wang S; Xiao L; Zhu J; Wu Q; Lai X; Zhang Q; Chen J; Li T
Front Neurosci; 2021; 15():641284. PubMed ID: 33994921
[TBL] [Abstract][Full Text] [Related]
78. Glutamate carboxypeptidase II: an overview of structural studies and their importance for structure-based drug design and deciphering the reaction mechanism of the enzyme.
Pavlícek J; Ptácek J; Barinka C
Curr Med Chem; 2012; 19(9):1300-9. PubMed ID: 22304708
[TBL] [Abstract][Full Text] [Related]
79. Localization of NAAG-related gene expression deficits to the anterior hippocampus in schizophrenia.
Ghose S; Chin R; Gallegos A; Roberts R; Coyle J; Tamminga C
Schizophr Res; 2009 Jun; 111(1-3):131-7. PubMed ID: 19403271
[TBL] [Abstract][Full Text] [Related]
80. Label-free determination of prostate specific membrane antigen in human whole blood at nanomolar levels by magnetically assisted surface enhanced Raman spectroscopy.
Chaloupková Z; Balzerová A; Bařinková J; Medříková Z; Šácha P; Beneš P; Ranc V; Konvalinka J; Zbořil R
Anal Chim Acta; 2018 Jan; 997():44-51. PubMed ID: 29149993
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
